Abstract: The present disclosure relates to a method of treating or reducing adhesions in the peritoneum of a patient in need thereof. The method includes performing adhesiolysis on one or more adhesions involving the patient's peritoneum and/or one or more tissues or organs in the patient's peritoneal cavity; and administering to the peritoneum or the peritoneal cavity of the patient an effective amount of a composition comprising at least one glutamine source. The glutamine source is selected from one or more of L-glutamine, physiologically acceptable salts of L-glutamine, and dipeptides comprising L-glutamine.

Abstract: Intraperitoneal administration of glutamine to reduce adhesions in the peritoneum of a patient.

Abstract: Intraperitoneal administration of glutamine to reduce adhesions in the peritoneum of a patient.

Abstract: Intraperitoneal administration of glutamine to reduce adhesions in the peritoneum of a patient.

Abstract: Intraperitoneal administration of glutamine to reduce adhesions in the peritoneum of a patient.

Abstract: Due to a long-standing interest in scar reduction, alanyl-glutamine was tested for ability to treat keloid scars, despite the difficulties associated with delivering compounds above a certain size threshold across the skin barrier to the dermis where new skin is formed. Surprisingly, it was found that a dermal application formulation of alanyl-glutamine was effective in reducing the severity and/or preventing the formation of keloid scars.

Abstract: Intraperitoneal administration of glutamine reduces post-operative adhesion formation.

Abstract: Glutamine source formulations that have release profiles that provide for sustained release via intraperitoneal administration of glutamine reduces post-operative adhesion formation.